JP2020526515A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526515A5 JP2020526515A5 JP2020500140A JP2020500140A JP2020526515A5 JP 2020526515 A5 JP2020526515 A5 JP 2020526515A5 JP 2020500140 A JP2020500140 A JP 2020500140A JP 2020500140 A JP2020500140 A JP 2020500140A JP 2020526515 A5 JP2020526515 A5 JP 2020526515A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- mineral
- interferon
- ribonucleic acid
- combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 60
- 239000011707 mineral Substances 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 40
- 102000014150 Interferons Human genes 0.000 claims description 28
- 108010050904 Interferons Proteins 0.000 claims description 28
- 229940079322 interferon Drugs 0.000 claims description 28
- 229920002477 rna polymer Polymers 0.000 claims description 26
- 239000003112 inhibitor Substances 0.000 claims description 24
- 102000026949 interferon binding proteins Human genes 0.000 claims description 17
- 108091008479 interferon binding proteins Proteins 0.000 claims description 17
- 239000011859 microparticle Substances 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 150000003384 small molecules Chemical class 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- PDOQBOJDRPLBQU-QMMMGPOBSA-N 5-chloro-2-n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=1)=NC=C(Cl)C=1NC=1C=C(C)NN=1 PDOQBOJDRPLBQU-QMMMGPOBSA-N 0.000 claims description 4
- 101150023320 B16R gene Proteins 0.000 claims description 4
- 101150096427 I3L gene Proteins 0.000 claims description 4
- 101710128560 Initiator protein NS1 Proteins 0.000 claims description 4
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 4
- 101800000268 Leader protease Proteins 0.000 claims description 4
- 101000915697 Machupo virus RING finger protein Z Proteins 0.000 claims description 4
- UKBGBACORPRCGG-UHFFFAOYSA-N N-[3-[[5-cyclopropyl-2-[3-(4-morpholinylmethyl)anilino]-4-pyrimidinyl]amino]propyl]cyclobutanecarboxamide Chemical compound C1CCC1C(=O)NCCCNC(C(=CN=1)C2CC2)=NC=1NC(C=1)=CC=CC=1CN1CCOCC1 UKBGBACORPRCGG-UHFFFAOYSA-N 0.000 claims description 4
- 241001244466 New world arenaviruses Species 0.000 claims description 4
- 101710144127 Non-structural protein 1 Proteins 0.000 claims description 4
- 101800001014 Non-structural protein 5A Proteins 0.000 claims description 4
- 239000004012 Tofacitinib Substances 0.000 claims description 4
- 101100316831 Vaccinia virus (strain Copenhagen) B18R gene Proteins 0.000 claims description 4
- 101100287474 Vaccinia virus (strain Copenhagen) K3L gene Proteins 0.000 claims description 4
- 101100287475 Vaccinia virus (strain Western Reserve) VACWR034 gene Proteins 0.000 claims description 4
- 101100004099 Vaccinia virus (strain Western Reserve) VACWR200 gene Proteins 0.000 claims description 4
- 239000000919 ceramic Substances 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 150000002739 metals Chemical class 0.000 claims description 4
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 4
- 229960000215 ruxolitinib Drugs 0.000 claims description 4
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 4
- 229960001350 tofacitinib Drugs 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052789 astatine Inorganic materials 0.000 claims description 2
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 239000002479 lipoplex Substances 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- FDKVVSDXZNIXAN-UHFFFAOYSA-N carbamic acid;2-ethyl-2-(hydroxymethyl)propane-1,3-diol Chemical compound NC(O)=O.NC(O)=O.NC(O)=O.CCC(CO)(CO)CO FDKVVSDXZNIXAN-UHFFFAOYSA-N 0.000 claims 1
- 239000008199 coating composition Substances 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 26
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- SAYGKHKXGCPTLX-UHFFFAOYSA-N 2-(carbamoylamino)-5-(4-fluorophenyl)-3-thiophenecarboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C=CC(F)=CC=2)=C1 SAYGKHKXGCPTLX-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762528566P | 2017-07-05 | 2017-07-05 | |
| US62/528,566 | 2017-07-05 | ||
| PCT/US2018/040928 WO2019010310A1 (en) | 2017-07-05 | 2018-07-05 | MINERAL-COATED MICROPARTICLES FOR CO-ADMINISTRATION OF ANTI-INFLAMMATORY MOLECULES AND NUCLEIC ACIDS TO IMPROVE GENE DELIVERY RESULTS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020526515A JP2020526515A (ja) | 2020-08-31 |
| JP2020526515A5 true JP2020526515A5 (https=) | 2021-08-05 |
Family
ID=64950341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500140A Pending JP2020526515A (ja) | 2017-07-05 | 2018-07-05 | 遺伝子送達成果を改善する核酸と抗炎症性分子の共送達のためのミネラルコーティングされたマイクロ粒子 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11065208B2 (https=) |
| EP (1) | EP3648750A4 (https=) |
| JP (1) | JP2020526515A (https=) |
| CN (1) | CN111050757A (https=) |
| CA (1) | CA3068917A1 (https=) |
| WO (1) | WO2019010310A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018187344A1 (en) | 2017-04-03 | 2018-10-11 | Wisconsin Alumni Research Foundation | Mineral coated microparticles for sustained delivery of biologically active molecules |
| CA3068917A1 (en) * | 2017-07-05 | 2019-01-10 | Wisconsin Alumni Research Foundation | Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes |
| WO2022031594A1 (en) * | 2020-08-06 | 2022-02-10 | Dianomi Therapeutics, Inc. | Compositions and methods for vaccine delivery |
| WO2022051247A1 (en) * | 2020-09-01 | 2022-03-10 | Dianomi Therapeutics, Inc. | Methods for treating or preventing inflammatory events |
| CN115227676B (zh) * | 2022-07-04 | 2023-10-24 | 浙江大学 | 一种缓释mRNA的矿物包被微粒材料及其制备方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080317807A1 (en) * | 2007-06-22 | 2008-12-25 | The University Of Hong Kong | Strontium fortified calcium nano-and microparticle compositions and methods of making and using thereof |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9862926B2 (en) * | 2011-06-27 | 2018-01-09 | Cellscript, Llc. | Inhibition of innate immune response |
| CN104508131B (zh) | 2012-05-21 | 2018-11-23 | 加利福尼亚大学董事会 | 通过合成的自我复制的RNA形成人iPS细胞 |
| US20160017368A1 (en) * | 2013-02-19 | 2016-01-21 | Wisconsin Alumni Research Foundation | Inorganic coatings for the enhancement of chemical transfection |
| EP3046933B1 (en) * | 2013-09-18 | 2019-02-27 | BCN Peptides, S.A. | Cortistatin analogues for the treatment of inflammatory and/or immune diseases |
| CA3068917A1 (en) * | 2017-07-05 | 2019-01-10 | Wisconsin Alumni Research Foundation | Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes |
-
2018
- 2018-07-05 CA CA3068917A patent/CA3068917A1/en active Pending
- 2018-07-05 WO PCT/US2018/040928 patent/WO2019010310A1/en not_active Ceased
- 2018-07-05 US US16/626,973 patent/US11065208B2/en active Active
- 2018-07-05 JP JP2020500140A patent/JP2020526515A/ja active Pending
- 2018-07-05 EP EP18828119.0A patent/EP3648750A4/en not_active Withdrawn
- 2018-07-05 CN CN201880056388.3A patent/CN111050757A/zh active Pending
-
2021
- 2021-07-19 US US17/379,351 patent/US11779542B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526515A5 (https=) | ||
| Xia et al. | TGFβ reprograms TNF stimulation of macrophages towards a non-canonical pathway driving inflammatory osteoclastogenesis | |
| Yokoyama et al. | Inhibition of EP4 signaling attenuates aortic aneurysm formation | |
| WO2017180917A3 (en) | Lipid compositions and their uses for intratumoral polynucleotide delivery | |
| JP2016518331A5 (https=) | ||
| NZ553828A (en) | Method of treating an inflammatory disease by double stranded ribonucleic acid by inhibiting TNF-alpha | |
| JP2017534285A5 (https=) | ||
| WO2005047477A3 (en) | Interspersed repetitive element rnas as substrates, inhibitors and delivery vehicles for rnai | |
| JP2015535853A5 (https=) | ||
| WO2006081546A3 (en) | Inhibitor nucleic acids | |
| JP2011511004A5 (https=) | ||
| JP2015519047A5 (https=) | ||
| JP2016519138A5 (https=) | ||
| JP2020513033A5 (https=) | ||
| JP2015522264A5 (https=) | ||
| JP2019519533A5 (https=) | ||
| JP2014515377A5 (https=) | ||
| JP2015520178A5 (https=) | ||
| JP2019501202A5 (https=) | ||
| JP2011504874A5 (https=) | ||
| JP2019517262A5 (https=) | ||
| JP2016538306A5 (https=) | ||
| WO2019028246A3 (en) | METHODS OF TREATING GENETIC HEARING LOSS | |
| RU2012140651A (ru) | Фармацевтический или нутрицевтический состав | |
| EA200501513A1 (ru) | Замещённые 1, 4 - диазепины и их применения |